How can pharma facilities meet strict compliance standards, lower operational costs, and still reduce their environmental impact?
Pharmaceutical manufacturing facilities face increasing pressure to reduce their environmental footprint while maintaining strict regulatory compliance and cost efficiency. Yet, aligning these goals is not only possible—it can lead to powerful synergies. For example, one session will cover how heating, ventilation, and air conditioning (HVAC) systems, which often account for 50–80% of a facility's energy use, present a major opportunity. With smart design focused on efficiency and sustainability for HVAC and other systems, manufacturers can reduce energy consumption, improve cleanroom performance, and still meet the stringent requirements of Annex 1.
Building a strong business case for sustainability is also essential to secure leadership support and funding. This means connecting environmental initiatives to financial returns, risk mitigation, and strategic value through tools like lifecycle cost analysis and stakeholder engagement. As new regulations and environmental, social, and governance (ESG) expectations rise, frameworks like LEED v5 are also evolving, emphasizing carbon reduction, transparency, and climate resilience. A session will outline how frameworks like LEED v5 support compliance and can also help pharma companies demonstrate measurable sustainability outcomes to investors, regulators, and the public. Attendees will gain insight into how integrating technical, financial, and strategic perspectives helps pharma companies build high-performing, future-ready facilities—balancing compliance, cost efficiency, and sustainability.
Turning Insights into Action Across Facilities, Operations, and Construction
Data is essential for driving sustainability in the pharmaceutical industry. By analyzing energy consumption and greenhouse gas emissions, companies can identify opportunities to reduce waste and improve efficiency. For example, a planned session in this track will showcase how one pharmaceutical facility used a $10 million capital expenditure investment to cut Scope 1 emissions by 67% within a year, saving over $1 million annually in operating expenses. A site-wide audit provided actionable insights, prioritizing energy-saving projects aligned with corporate sustainability targets.
Johnson & Johnson will also present on how they are tackling embodied carbon in construction projects through lifecycle assessments, aiming to reduce their carbon footprint and integrate sustainability into every phase of building development. These examples demonstrate how leveraging data and collaboration can effectively drive sustainability efforts across facilities, operations, and construction.
How Crisis Preparedness, Supply Chain Strategy, and Environmental Innovation are Shaping the Industry's Future
Resilience and sustainability are converging into a unified strategy that drives both operational continuity and environmental progress. When Hurricane Helene struck the East Coast of the United States in 2024, the largest supplier of intravenous fluids faced a critical test of its emergency preparedness. A session in this track will cover how emergency planning, risk assessment and remediation strategies, including the use of automated vaporized hydrogen peroxide treatment for biological decontamination, can support swift and cost-effective recovery. Attendees will gain insight into the emergency response, decision-making, and success measurement—providing practical comparisons for strengthening their own crisis strategies.
The industry is advancing collective resilience. One session will share pandemic-era lessons from a three-day workshop with 25 biomanufacturers and 10 key suppliers. Ongoing efforts to establish an industry-wide crisis response mechanism highlight the importance of digitized supply chains within Pharma 4.0.
Participants will also learn how strategic planning, supplier prequalification, and cross-sector coordination can reinforce business continuity—and how initiatives like Sanofi’s Planet Care and its partnership with McLaren are accelerating decarbonization through innovation. Together, these examples show how climate resilience, regulatory alignment, and sustainability create a competitive advantage for the future of pharma.
Reinventing Pharma Supply Chains for Resilience, Efficiency, and Patient Equity
In a world of uncertainty, resilience is key for the pharmaceutical industry. Strategies in upcoming sessions will focus on preparing for disruptions, responding to crises, and ensuring seamless operations.
For example, Endress+Hauser’s proven resilience practices, including sustainability efforts and AI-driven strategies, will be highlighted. The session will explore the root causes of drug shortages, such as inadequate incentives for less profitable drugs and regulatory challenges and propose solutions like enhanced data sharing and risk management plans.
Astellas Pharma’s Strategic Outsourcing and Relationships (SOAR) Model will also be presented in the session “Merging, Managing, and Scaling Supply Chain Resilience” as a framework for improving governance, visibility, and risk mitigation across global operations. This model has allowed Astellas to enhance forecasting, reduce costs, and improve supplier relationships. Attendees will leave with actionable strategies to strengthen supply chain resilience, optimize risk management, and improve operational efficiency in the evolving pharmaceutical landscape.
Building Smarter, Safer, and Greener Pharma
Pharmaceutical companies are increasingly focusing on safety, well-being, and carbon reduction through innovative strategies. One session will highlight how Promega's Chappelle Manufacturing Center integrates 3D visualizations and human-centric design to improve safety, enhance workforce satisfaction, and optimize efficiency in high-hazard environments.
In a different but equally impactful effort, AstraZeneca’s Mt. Vernon, Indiana facility has made significant strides toward environmental sustainability, achieving near-zero scope 1 and 2 carbon emissions by reducing energy demand and increasing its renewable energy footprint. Together, these examples illustrate how innovation can drive both human-centered design and environmental responsibility in pharmaceutical operations.
Conclusion
This track at the 2025 ISPE Annual Meeting & Expo highlights the pharmaceutical industry's growing focus on sustainability, resilience, and innovation. With a focus on practical solutions for reducing environmental impact, strengthening supply chain stability, and improving workplace safety, we’re paving the way for the future of pharma.
Join ISPE to connect with industry leaders, share your insights, and be part of the conversation that will drive meaningful change. ISPE looks forward to connecting with attendees at the conference, whether in person or virtually, as the industry comes together to shape a more sustainable and resilient future for the industry.
Learn more and register today
